The Icagen/Yamanouchi collaboration in dementia, including Alzheimer's disease, which began in 2000, provided for an initial upfront payment, research funding and milestone payments
Sanofi-Synthelabo said earlier this month it would push for 100 per cent control of its former rival and newly-acquired subsidiary Aventis after the French Financial Market Authority.
With the RFID pharmaceutical market heating up fast, four players merged Wednesday to form NEXT GENeSYS Corp., a new public company with a projected market capitalization of $65 million.
NitroMed shares climbed higher Wednesday after the pharmaceutical company reported that it plans to hire a sales force for its new congestive heart failure drug
Spectrum Pharmaceuticals, Inc. announced that an abstract from the ongoing Phase 2 trial evaluating elsamitrucin as a single agent for the treatment of relapsed or refractory non-Hodgkin's lymphoma
